Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CBX7 | O95931 | 3/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5116400 | 0.86 | TSHR (0.56) | ALDH1A1NPC1ALOX15TSHRGRM5 | |
| SCHEMBL5123930 | 0.84 | HTR4 (0.44) | ALDH1A1NPC1ALOX15TSHRGRM5 | |
| SCHEMBL5128669 | 0.82 | SPR (0.42) | ALDH1A1GRM5MEN1KMT2A | |
| SCHEMBL5114700 | 0.80 | GRM5 (0.46) | GRM5 | |
| SCHEMBL5128749 | 0.80 | NPC1 (0.48) | NPC1GRM5POLB | |
| SCHEMBL5129247 | 0.80 | GRM5 (0.48) | ALDH1A1LMNANPC1GRM5HTT | |
| SCHEMBL5123256 | 0.78 | CYP3A4 (0.47) | ALDH1A1LMNAALOX15TSHRGRM5 | |
| SCHEMBL5124159 | 0.78 | SMN1; SMN2 (0.52) | ALDH1A1LMNATSHRGRM5HTT | |
| SCHEMBL5130117 | 0.77 | GRM5 (0.44) | ALDH1A1LMNAALOX15TSHRGRM5 | |
| SCHEMBL5125423 | 0.77 | GRM5 (0.48) | GRM5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269250-A1 | Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists | GRM5, GRIK5, GRM1 | ALDH1A1 908/4885LMNA 4443/4885NPC1 1498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.